Institute of Academic Medicine and Weill Cornell Medical College, Houston Methodist Cancer Center, Houston, TX, USA.
Division of Internal Medicine, Section of Nephrology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Adv Exp Med Biol. 2020;1244:287-293. doi: 10.1007/978-3-030-41008-7_16.
With the increasing use of immunotherapy, there has been an associated increased survival in many cancers but has also resulted in unregulated organ-specific toxicities. In this chapter, we discuss the renal toxicities associated with a checkpoint inhibitor (CPI) from the typical acute tubulointersitial nephritis to glomerulonephritis, their proposed mechanisms, and treatments. We also discuss the use of CPI and reactivation of preexisting auto-immune diseases and focus on renal cell cancer in setting of Chronic kidney disease (CKD). Transplant rejection in the setting of CPI use is yet to be further studied, and available data is presented in this chapter.
随着免疫疗法的应用日益增多，许多癌症的生存率都有所提高，但也导致了不受调节的器官特异性毒性。在本章中，我们讨论了与检查点抑制剂（CPI）相关的肾毒性，从典型的急性肾小管间质性肾炎到肾小球肾炎，讨论其可能的发病机制和治疗方法。我们还讨论了 CPI 的使用与先前自身免疫性疾病的再激活，以及在慢性肾脏病（CKD）背景下的肾细胞癌。CPI 使用背景下的移植排斥反应还有待进一步研究，本章介绍了现有数据。
